Replies to post #214567 on Avid Bioservices Inc (CDMO)

[bidrite]

Mary J. Boyd, Ph.D.
Head of Business Development for Asia and Europe
Dr. Boyd has more than 20 years of international pharmaceutical and biotechnology business development experience with large pharmaceutical companies including GlaxoSmithKline, Novartis and Roche. Dr. Boyd was previously director, Asia, worldwide business development, R&D for GlaxoSmithKline; head of business development and licensing in Japan for Novartis; and head, licensing and patent group for Roche in Japan. In these positions, she identified new opportunities, negotiated global agreements and maintained productive relationships with other companies. Dr. Boyd holds a Ph.D. in Developmental Genetics from the University of Cambridge, UK and a B.Sc. in Biochemistry from the University of Sussex, UK.

And she is the world's greatest distance runner to boot. Forrest Gump has nothing on her.

[InternetForumUser]

Mary J. Boyd was hired in July 2007, which was almost 8 years ago. Per the Peregrine News Release, they stated the following:

..today announced the appointment of Mary J. Boyd, Ph.D. as head of business development for Asia and Europe. Dr. Boyd has more than 20 years of international pharmaceutical and biotechnology business development experience with large pharmaceutical companies including GlaxoSmithKline, Novartis and Roche. She will focus on identifying potential partners and negotiating agreements for Peregrine's extensive clinical and preclinical assets in Asian and European markets.

So how many Partnerships has Peregrine had since here hiring? The STASON Partnership which as everyone knows brought a ton of value for the Shareholders.

So you think that over the next 8 years, Mary Boyd will continue to be super busy and FOCUSED on Identifying those Partners? Maybe she will find one who will actually sign on the dotted line.